α-lipoic acid, diabetic neuropathy, and Nathan's prophecy

Angiology

Volumn 63, Issue 2, 2012, Pages 81-83

  Papanas, N ^a   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

alpha lipoic acid; diabetes mellitus; diabetic neuropathy; oxidative stress; vascular complications

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; THIOCTIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DIABETIC DISTAL SYMMETRIC POLYNEUROPATHY; DIABETIC NEUROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENDOCARDIAL DISEASE; FOLLOW UP; HUMAN; INFECTION; INJURY; MYOCARDIAL DISEASE; NONHUMAN; PERICARDIAL DISEASE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NERVE CONDUCTION; TREATMENT DURATION;

CLINICAL TRIALS AS TOPIC; DIABETIC NEUROPATHIES; HUMANS; THIOCTIC ACID; TREATMENT OUTCOME;

EID: 84856065932     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711421165     Document Type: Article

References (24)

1. Sugimoto K, Murakawa Y, Sima AA.. Diabetic neuropathy-a continuing enigma. Diabetes Metab Res Rev. 2000 ; 16 (6). 408-433
2. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996 ; 39 (3). 329-335 (Pubitemid 26066803)
3. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 ; 352 (4). 341-350
4. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A.. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008 ; 31 (3). 464-469
5. Albers JW, Herman WH, Pop-Busui R, et al. and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010 ; 33 (5). 1090-1096
6. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 ; 376 (9739). 419-430
7. Ziegler D, Roden M.. Near-normoglycaemia prevents the development of polyneuropathy. A 24-year prospective study from the diagnosis of type 1 diabetes. Diabetologia. 2010 ; 53 (suppl 1). S16 - A25
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 ; 348 (5). 383-393 (Pubitemid 36159355)
9. Fioretto P, Dodson PM, Ziegler D, Rosenson RS.. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010 ; 6 (1). 19-25
10. Bril V, Buchanan RA.. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2006 ; 29 (1). 68-72 (Pubitemid 44033433)
11. Casellini CM, Barlow PM, Rice AL, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007 ; 30 (4). 896-902 (Pubitemid 46556584)
12. Papanas N, Maltezos E.. Cilostazol in diabetic neuropathy: premature farewell or new beginning?. Angiology. [published online ahead of print April 20, 2011].
13. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 ; 29 (11). 2365-2370 (Pubitemid 44912237)
14. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA.. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysis. Diabet Med. 2004 ; 21 (2). 114-121 (Pubitemid 38221809)
15. Ziegler D.. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004 ; 3 (3). 173-189 (Pubitemid 38724503)
16. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 ; 16 (12). 1040-1043 (Pubitemid 30051432)
17. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999 ; 31 (3). 171-179 (Pubitemid 29435878)
18. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 ; 38 (12). 1425-1433
19. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999 ; 22 (8). 1296-1301 (Pubitemid 29350240)
20. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 ; 26 (3). 770-776 (Pubitemid 36929342)
21. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with {alpha}-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. [published online ahead of print July 25, 2011].
22. Tesfaye S, Tandan R, Bastyr EJ 3rd, et al. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care. 2007 ; 30 (10). 2626-2632 (Pubitemid 47547808)
23. Rathmann W, Haastert B, Delling B, Gries FA, Giani G.. Postmarketing surveillance of adverse drug reactions: a correlational study approach using multiple data sources. Pharmacoepidemiol Drug Saf. 1998 ; 7 (1). 51-57 (Pubitemid 28138973)
24. Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007 ; 30 (3). 664-669 (Pubitemid 46354350)